H.R. 1794 (119th)Bill Overview

United States-Abraham Accords Cooperation and Security Act of 2025

Health|Health
Cosponsors
Support
Bipartisan
Introduced
Mar 3, 2025
Discussions
Bill Text
Current stageCommittee

Referred to the House Committee on Energy and Commerce.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

The bill directs the Secretary of Health and Human Services, through the FDA Commissioner, to establish an "Abraham Accords Office" within the FDA. The Office must be set up in an Abraham Accords country within two years, provide technical assistance to regulatory authorities and manufacturers there, facilitate FDA interactions and information-sharing on U.S. regulatory pathways, and follow national security guidance.

Why people may split

Left emphasizes global health benefits and regulatory capacity building

Watch point

Administrative, narrow bill likely to attract bipartisan support, though foreign-policy critics could object.

The bill directs the Secretary of Health and Human Services, through the FDA Commissioner, to establish an "Abraham Accords Office" within the FDA.

The Office must be set up in an Abraham Accords country within two years, provide technical assistance to regulatory authorities and manufacturers there, facilitate FDA interactions and information-sharing on U.S. regulatory pathways, and follow national security guidance.

The Secretary must report to Congress within three years evaluating the Office’s progress, activities, and recommendations for improved coordination.

Passage60/100

Narrow, technical, and administratively focused bills often pass; main hurdles are funding and any partisan foreign-policy opposition.

CredibilityPartial

How solid the drafting looks.

Contention55/100

Left emphasizes global health benefits and regulatory capacity building

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Cities · ManufacturersFederal agencies

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • CitiesStrengthening partner countries' regulatory capacity could improve the quality and safety of exported medical products.
  • ManufacturersConvergence toward FDA standards may reduce duplication and speed market access for compliant manufacturers.
  • Potential benefitImproved regulatory cooperation could enhance supply chain resilience for critical medical goods.
Likely burdened
  • Federal agenciesEstablishing and staffing a foreign FDA office will require federal funding and could divert agency resources.
  • Potential burdenLocating an FDA office abroad may raise national security, personnel protection, and diplomatic complexities.
  • Potential burdenSharing regulatory pathways and information may create confidentiality or intellectual property concerns for companies.
03 · Why people split

Why the argument around this bill splits.

Left emphasizes global health benefits and regulatory capacity building
Progressive80%

Likely supportive of international regulatory cooperation that can improve product safety and access.

Would emphasize public-health benefits while pressing for transparency, equity, and safeguards against corporate capture or human-rights tradeoffs.

Leans supportive
Centrist75%

Pragmatic and generally favorable to harmonizing regulatory standards and improving coordination with strategic partners.

Would seek clearer metrics, cost estimates, and oversight to ensure the Office is effective and not duplicative.

Leans supportive
Conservative35%

Skeptical about expanding U.S. federal bureaucracy abroad; supportive of allied cooperation but wary of overseas offices, unspecified costs, and potential national security or sovereignty issues.

Prefers market-based or bilateral regulatory arrangements.

Likely resistant
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood60/100

Narrow, technical, and administratively focused bills often pass; main hurdles are funding and any partisan foreign-policy opposition.

Scope and complexity
24%
Scopenarrow
24%
Complexitylow
Why this could stall
  • No explicit authorization of appropriations included
  • Which countries qualify as Abraham Accords countries
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Left emphasizes global health benefits and regulatory capacity building

Narrow, technical, and administratively focused bills often pass; main hurdles are funding and any partisan foreign-policy opposition.

Unlocked analysis

Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for United States-Abraham Accords Cooperation and Security Act of…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis